BCL2 and gastric cancer: Additionally, western blots showed inhibition of ESPL1 could significantly down-regulate the p-AKT1/2/3, VEGF and BCL-2 protein levels after apatinib treatment, which demonstrated ESPL1 inhibition sensitized GC cells to apatinib might through suppressing cell proliferation and promoting apoptosis.